Neurogene Inc. Payments to Acquire Available-for-sale Securities
Neurogene Inc. (NGNE) reported Payments to Acquire Available-for-sale Securities of $6.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-03-12
- Neurogene Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Neurogene Inc. payments to acquire available-for-sale securities for the quarter ending 2016-12-31 was $50.11M.
- Neurogene Inc. payments to acquire available-for-sale securities for the quarter ending 2016-09-30 was $21.78M.
- Neurogene Inc. payments to acquire available-for-sale securities for the quarter ending 2016-06-30 was $21.55M.
- Neurogene Inc. payments to acquire available-for-sale securities for fiscal 2017 was $6.00M, a 94.37% decline from fiscal 2016.
- Neurogene Inc. payments to acquire available-for-sale securities for fiscal 2016 was $106.44M, a 75.35% increase from fiscal 2015.
- Neurogene Inc. payments to acquire available-for-sale securities for fiscal 2015 was $60.70M, a 66.42% increase from fiscal 2014.
- Neurogene Inc. payments to acquire available-for-sale securities for fiscal 2014 was $36.48M, a 1192.98% increase from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 6 month as first filed | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 9 month as first filed | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $6.00M 10-K · filed 2020-03-12 | |||||
| 2017-09-30 | $6.00M 10-Q · filed 2018-11-07 | ||||||
| 2016-12-31 | $50.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $71.89M derived: sum of 2 quarters · filed 2019-03-07 | $93.44M derived: sum of 3 quarters · filed 2019-03-07 | $106.44M 10-K · filed 2019-03-07 | |||
| 2016-09-30 | $21.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $43.33M derived: sum of 2 quarters · filed 2017-11-08 | $56.34M 10-Q · filed 2017-11-08 | ||||
| 2016-06-30 | $21.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $34.56M 10-Q · filed 2017-08-08 | |||||
| 2016-03-31 | $13.00M 10-Q · filed 2017-05-09 | ||||||
| 2015-12-31 | $60.70M 10-K · filed 2018-03-12 | ||||||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-06 | ||||||
| 2014-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $2.00M derived: sum of 2 quarters · filed 2017-03-09 | $36.47M derived: sum of 3 quarters · filed 2017-03-09 | $36.48M 10-K · filed 2017-03-09 | $36.47M 10-K · filed 2015-03-16 | ||
| 2014-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $36.47M derived: sum of 2 quarters · filed 2015-11-10 | $36.47M 10-Q · filed 2015-11-10 | $36.47M 10-Q · filed 2014-11-04 | |||
| 2014-06-30 | $34.47M 10-Q · filed 2014-08-11 | $34.48M 10-Q · filed 2015-08-06 | $34.47M 10-Q · filed 2014-08-11 | ||||
| 2013-12-31 | $2.82M 10-K · filed 2016-03-14 | $2.82M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |